A pilot study of the pharmacokinetics and triglyceride lowering activity of acipimox in dialyzed uremic patients.
The pharmacokinetics of acipimox was studied in 6 dialyzed uremic patients given single oral doses of 50 mg. Acipimox was not significantly eliminated outside dialysis, whereas during dialysis it was efficiently cleared with plasma, t 1/2 is about 2.6 hours. Accordingly, a dosage schedule of 50 mg or 100 mg of acipimox after each dialysis session was selected for a second, 4-week study in 14 uremic patients with hypertriglyceridemia. Acipimox plasma levels, monitored during the study, proved in agreement with those expected on a theoretical pharmacokinetic basis. A clear-cut reduction of serum triglyceride levels was also achieved.
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011719:Pyrazines / Q000008:administration & dosage / Q000378:metabolism*; D006435:Renal Dialysis; D013997:Time Factors; D014280:Triglycerides / Q000378:metabolism*; D014511:Uremia / Q000378:metabolism*
D000960:Hypolipidemic Agents; D011719:Pyrazines; D014280:Triglycerides; C027696:acipimox